Nexvet Biopharma plc (NVET) [Rocket]

In millions, except per share items	Jun-30-16	Jun-30-15	Jun-30-14	Jun-30-13
	10-K	10-K	10-K	10-K
Revenues [+]	0.2	0.0	0.0	0.3
Licensing				0.2
Royalties	14.9	9.8	5.6
Other		0.0	0.0	0.1
Revenue growth	700.0%	92.3%	-96.0%
Cost of goods sold	0.2	0.4	0.0	0.0
Gross profit	0.0	-0.4	0.0	0.3
Gross margin	0.0%	-1500.0%	100.0%	100.0%
Selling, general and administrative [+]	7.3	10.2	4.4	2.1
General and administrative	7.3	10.2	4.4	2.1
Research and development	14.9	9.8	5.6	2.7
Other operating expenses	0.1	-0.3
EBITDA [+]	-21.7	-20.0	-10.0	-4.5
EBITDA growth	8.7%	100.2%	122.4%
EBITDA margin	-10854.0%	-79856.0%	-76723.1%	-1363.2%
Depreciation and amortization	0.5	0.2	0.1	0.0
EBIT [+]	-22.2	-20.1	-10.0	-4.5
EBIT growth	10.5%	100.6%	123.1%
EBIT margin	-11112.0%	-80472.0%	-77153.8%	-1366.6%
Non-recurring items [+]	-0.1	-0.1
Asset impairment	-0.1	-0.1
Interest income	0.2	0.1	0.0	0.0
Interest income	0.2	0.1	0.0	0.0
Other income (expense), net [+]	2.7	8.1	3.3	1.2
Gain (loss) on foreign currency transactions	0.2	4.2	-0.4
Other	0.2	4.2	-0.4
Pre-tax income	-19.4	-11.9	-6.7	-3.2
Income taxes	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%
Net income	-19.4	-11.9	-6.7	-3.2
Net margin	-9682.5%	-47428.0%	-51615.4%	-985.1%

Basic EPS [+]	($1.68)	($2.27)	($6.70)	($3.62)
Growth	-26.1%	-66.1%	85.1%
Diluted EPS [+]	($1.68)	($2.27)	($6.70)	($3.62)
Growth	-26.1%	-66.1%	85.1%

Shares outstanding (basic) [+]	11.5	5.2	1.0	0.9
Growth	120.9%	421.0%	11.9%
Shares outstanding (diluted) [+]	11.5	5.2	1.0	0.9
Growth	120.9%	421.0%	11.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.